investment@revazcapital.com
+91 22 42889999
LIC MF Healthcare Fund-Regular Plan-Growth
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 22-02-2019
AUM:
₹ 86.14 Cr
Expense Ratio
2.45%
Benchmark
BSE Healthcare TRI
ISIN
INF397L01LG2
Minimum Investment
5000.0
Minimum Topup
500.0
Minimum SIP Amount
200
Fund Manager
Mr. Karan Doshi
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| LIC MF Healthcare Fund-Regular Plan-Growth | -3.97 | 19.71 | 11.17 |
| Benchmark | - | - | - |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
29.0753
Last change
-0.33 (-1.1181%)
Fund Size (AUM)
₹ 86.14 Cr
Performance
16.84% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The objective of the Scheme is to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. There is no assurance that the investment objective of the Scheme will be achieved.
Fund Manager
Mr. Karan Doshi
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 10.85 |
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 6.08 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 5.7 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 5.68 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 4.74 |
| NEULAND LABORATORIES LIMITED EQ | 4.51 |
| FORTIS HEALTHCARE LIMITED. EQ | 4.48 |
| AUROBINDO PHARMA LIMITED EQ NEW F.V. RE.1/- | 4.46 |
| PIRAMAL PHARMA LIMITED EQ | 4.32 |
| STELIS BIOPHARMA LIMITED EQ NEW FV RE.1/- | 3.88 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 93.43 |
| Chemicals | 4.6 |
